Exome sequencing of extreme phenotypes in bronchopulmonary dysplasia

2019 ◽  
Vol 179 (4) ◽  
pp. 579-586
Author(s):  
Alice Hadchouel ◽  
Fabrice Decobert ◽  
Claude Besmond ◽  
Christophe Delacourt
2015 ◽  
Vol 192 (5) ◽  
pp. 589-596 ◽  
Author(s):  
Jingjing Li ◽  
Kun-Hsing Yu ◽  
John Oehlert ◽  
Laura L. Jeliffe-Pawlowski ◽  
Jeffrey B. Gould ◽  
...  

2015 ◽  
Vol 41 (S1) ◽  
Author(s):  
Marco Somaschini ◽  
◽  
Chiara Di Resta ◽  
Chiara Volonteri ◽  
Emanuela Castiglioni ◽  
...  

Hepatology ◽  
2015 ◽  
Vol 62 (2) ◽  
pp. 429-439 ◽  
Author(s):  
Christine E. McLaren ◽  
Mary J. Emond ◽  
V. Nathan Subramaniam ◽  
Pradyumna D. Phatak ◽  
James C. Barton ◽  
...  

2013 ◽  
Vol 189 (4S) ◽  
Author(s):  
Shaheen Alanee ◽  
Sohela Shah ◽  
Kelly Stratton ◽  
Ilana Garcia-Grossman ◽  
Emily Zabor ◽  
...  

2018 ◽  
Vol 2 (9) ◽  
pp. 1021-1029 ◽  
Author(s):  
Sarah E. Kleinstein ◽  
Matthew Rein ◽  
Manal F. Abdelmalek ◽  
Cynthia D. Guy ◽  
David B. Goldstein ◽  
...  

Circulation ◽  
2014 ◽  
Vol 130 (suppl_2) ◽  
Author(s):  
Stuart Scott ◽  
Jean-Philippe Collet ◽  
Inga Peter ◽  
Yao Yang ◽  
Roger Hajjar ◽  
...  

There is wide interindividual variability in platelet aggregation in response to clopidogrel and high/low on-treatment platelet reactivity (HPR/LPR) is associated with more frequent adverse cardiovascular events. The CYP2C19*2 allele is the major genetic determinant of clopidogrel responsiveness but only accounts for ~12% of the variation thus urging for identification of additional variants. In a cohort of 636 coronary artery disease (CAD) patients, those with the most extreme pharmacodynamic response to clopidogrel were identified as LPR (P2Y12 reaction units (PRU)<50 and ADP-induced residual platelet aggregation (RPA)<5%) vs HPR (PRU>235 and RPA>60%). Four patients from each group with wild-type CYP2C19 ( *1/*1) were subjected to exome sequencing (average 70X). Identified variants that clustered in the LPR or HPR groups (3 or 4 carriers vs. 0) were identified and the probabilities of observing the clustering of each variant according to reported European minor allele frequencies (MAF) were calculated. Forty-nine of the identified variants with the lowest probablilities (18 LPR, 31 HPR, p<0.001) were genotyped across the remaining 628 coronary patients, which identified a significant association between two B4GALT2 variants (c.909C>T; p.Ile303= and c.366G>C; p.Gln122His, D’=0.68, r 2 =0.30) and treatment response. Carriers of c.909C>T (MAF=0.102) had lower PRU (p=0.0077) and RPA (p=0.0008) compared to non-carriers, as did carriers of c.366G>C (MAF=0.070) with lower PRU (p=0.0211) and RPA (p=0.0046). Notably, these effects were independent of CYP2C19*2 , suggesting an alternative biological pathway from clopidogrel metabolism. B4GALT2 is a platelet galactosyltransferase that catalyzes the biosynthesis of glycoconjugates and is involved in intercellular recognition and/or adhesion. Taken together, these data implicate B4GALT2 c.909C>T and c.366G>C as genetic determinants of clopidogrel sensitivity by directly influencing platelet aggregation. Their impact on clinical outcomes of CAD patients deserves further investigation.


2013 ◽  
Vol 31 (6_suppl) ◽  
pp. 300-300
Author(s):  
Shaheen Alanee ◽  
Sohela Shah ◽  
Kelly Lynn Stratton ◽  
Ilana Rebecca Garcia-Grossman ◽  
Emily Zabor ◽  
...  

300 Background: Little is known about germline variants predictive of response to chemotherapy in bladder cancer (BC). We investigated germline variants in patients (pts) treated with neoadjuvant gemcitabine/cisplatin (GC) under the hypothesis that responders and non-responders may differ in rare alleles predictive of treatment outcome. Methods: The Hiseq platform (≥ 20x coverage) was used to sequence the exomes of muscle-invasive (≥cT2) BC pts representing “extreme phenotypes” defined by response to neoadjuvant GC (complete responders vs. non responders). Responders were pT0N0 at cystectomy and remained disease free >1 year. Non-responders had residual disease in the bladder at cystectomy and metastatic disease either at cystectomy or within 1 year. Rare, potentially deleterious single nucleotide variants (SNVs) unique to these phenotypes were confirmed with Sequenom and validated in an independent group of BC pts treated with GC in the neoadjuvant or first line setting. One-sided Fisher’s exact test and multivariate logistic regression were used to estimate association between SNVs and response. Results: The discovery cohort had 6 responders (4 male) with a mean age of 62 and 9 non-responders (6 male) with a mean age of 63. Filtered exome sequences identified 93 rare/potentially deleterious SNVs unique to non-responders and 45 unique to responders of which 84 and 35 were confirmed by Sequenom, respectively. The independent validation cohort consisted of 173 pts, mean age 60, 72% male, and 53% responders (complete or partial). Among 119 SNVs genotyped in this cohort, only 3 responder and 9 non-responder SNVs were identified in ≥ 3 pts. None of the responder SNVs were associated with response. One non-responder SNV (rs150721903) was significantly associated with resistance to GC (OR: 9.7, 90% CI: 1.7-56.8, p=0.011), and remained significant after adjusting for risk score (p= 0.017). rs150721903 is a missense variant in an uncharacterized protein on chromosome 8. Conclusions: Exome sequencing of extreme phenotypes identified a variant that predicts resistance to GC, demonstrating the feasibility of this pharmacogenomics approach. Further evaluation of this SNV is warranted.


2019 ◽  
Vol 244 (11) ◽  
pp. 932-939 ◽  
Author(s):  
Gabriela Queila de Carvalho-Siqueira ◽  
Galina Ananina ◽  
Bruno Batista de Souza ◽  
Murilo Guimarães Borges ◽  
Mirta Tomie Ito ◽  
...  

Although sickle cell anemia results from homozygosity for a single mutation at position 7 of the β-globin chain, the clinical aspects of this condition are very heterogeneous. Complications include leg ulcers, which have a negative impact on patients’ quality of life and are related to the severity of the disease. Nevertheless, the complex pathogenesis of this complication has yet to be elucidated. To identify novel genes associated with leg ulcers in sickle cell anemia, we performed whole-exome sequencing of extreme phenotypes in a sample of Brazilian sickle cell anemia patients and validated our findings in another sample. Our discovery cohort consisted of 40 unrelated sickle cell anemia patients selected based on extreme phenotypes: 20 patients without leg ulcers, aged from 40 to 61 years, and 20 with chronic leg ulcers. DNA was extracted from peripheral blood leukocytes and used for whole-exome sequencing. After the bioinformatics analysis, eight variants were selected for validation by Sanger sequencing and TaqMan® genotyping in 293 sickle cell anemia patients (153 without leg ulcers) from two different locations in Brazil. After the validation, Fisher’s exact test revealed a statistically significant difference in a stop codon variant (rs12568784 G/T) in the FLG2 gene between the GT and GG genotypes ( P = 0.035). We highlight the importance of rs12568784 in leg ulcer development as this variant of the FLG2 gene results in impairment of the skin barrier, predisposing the individual to inflammation and infection. Additionally, we suggest that the remaining seven variants and the genes in which they occur could be strong candidates for leg ulcers in sickle cell anemia. Impact statement To our knowledge, the present study is the first to use whole-exome sequencing based on extreme phenotypes to identify new candidate genes associated with leg ulcers in sickle cell anemia patients. There are few studies about this complication; the pathogenesis remains complex and has yet to be fully elucidated. We identified interesting associations in genes never related with this complication to our knowledge, especially the variant in the FLG2 gene. The knowledge of variants related with leg ulcer in sickle cell anemia may lead to a better comprehension of the disease’s etiology, allowing prevention and early treatment options in risk genotypes while improving quality of life for these patients.


Sign in / Sign up

Export Citation Format

Share Document